backgroundth
complement
system
activ
liver
diseas
includ
acut
liver
failur
alf
howev
role
lectin
pathway
complement
scarc
investig
alf
pathway
initi
solubl
pattern
recognit
molecul
mannanbind
lectin
mbl
land
hficolin
predominantli
synthesis
liver
methodsserum
sampl
patient
enrol
us
alf
studi
group
collect
day
includ
healthi
blood
donor
cirrhosi
patient
control
analys
perform
use
sandwichtyp
immunoassay
elisa
trifma
resultsat
day
mbl
level
alf
patient
lower
compar
healthi
control
median
interquartil
rang
vs
increas
significantli
day
mficolin
level
lower
ml
vs
p
level
day
slightli
higher
compar
healthi
control
vs
signific
day
hand
lficolin
level
similar
healthi
control
spontan
alf
survivor
higher
level
mbl
day
vs
lower
level
lficolin
day
compar
patient
die
transplant
ml
vs
patient
acut
liver
failur
alf
decreas
level
function
activ
serum
complement
protein
observ
year
ago
defici
complement
cascad
known
associ
increas
infect
rate
poor
outcom
patient
sepsi
system
inflammatori
respons
syndrom
sir
autoinflammatori
diseas
featur
often
seen
alf
studi
alf
mice
complement
system
activ
increas
liverdeposit
complement
protein
correl
liver
damag
addit
complement
protein
knockout
mice
experi
reduc
liver
injuri
experiment
alf
current
literatur
thu
point
possibl
deleteri
role
complement
alf
previou
research
focus
classic
altern
pathway
complement
cascad
howev
recent
discov
lectin
pathway
scarc
investig
set
alf
singl
studi
indic
associ
level
mannanbind
lectin
mbl
outcom
hepat
failur
due
acut
hepat
b
infect
inflammatori
diseas
eg
rheumatoid
arthriti
lectin
pathway
contribut
pathogenesi
lectin
pathway
initi
solubl
pattern
recognit
protein
ie
mbl
l
hficolin
recogn
differ
pattern
carbohydr
acetylgroup
contain
ligand
pathogen
necrot
apoptot
cell
collectin
ficolin
circul
blood
recogn
respect
ligand
proteolyt
cleavag
complement
protein
initi
therebi
facilit
phagocytosi
cell
lysi
complement
activ
recognit
molecul
lectin
pathway
produc
liver
except
mficolin
origin
granulocyt
monocyt
hficolin
produc
hepatocyt
liver
epitheli
duct
cell
alveolar
cell
lung
product
site
summar
supplementari
materi
tabl
tabl
novel
protein
whose
structur
function
recent
describ
resembl
mbl
structur
hold
abil
bind
proteolyt
enzym
may
therefor
abl
initi
complement
cascad
never
investig
clinic
studi
liver
diseas
hypothes
level
lectin
pathway
protein
would
decreas
set
alf
sinc
primarili
synthes
liver
also
possibl
activ
consum
multiorgan
failur
furthermor
hypothes
lectin
pathway
protein
level
associ
clinic
outcom
therefor
aim
measur
level
solubl
pattern
recognit
protein
patient
alf
compar
healthi
control
evalu
whether
protein
level
associ
clinic
outcom
also
includ
group
patient
alcohol
cirrhosi
comparison
chronic
liver
diseas
us
alf
studi
group
consecut
enrol
patient
alf
conduct
longitudin
multicentr
cohort
studi
alf
patient
includ
within
inclus
period
follow
week
death
transplant
cohort
investig
previou
studi
group
patient
met
alf
criteria
coagulopathi
internation
normalis
ratio
inr
degre
hepat
encephalopathi
within
week
first
symptom
without
previou
underli
liver
diseas
inform
consent
obtain
next
kin
clinic
laboratori
data
enter
case
report
admiss
day
week
death
transplant
blood
sampl
biochem
analys
avail
day
admiss
patient
includ
serum
sampl
day
patient
patient
die
within
first
day
total
patient
die
transplant
entir
studi
period
serum
sampl
store
biobank
local
onsit
investig
use
standard
criteria
record
aetiolog
alf
addit
healthi
blood
donor
includ
control
patient
stabl
alcohol
liver
cirrhosi
recruit
routin
visit
outpati
clinic
studi
lectin
pathway
protein
set
chronic
liver
diseas
sign
acut
decompens
infect
diagnosi
alcohol
cirrhosi
base
relev
alcohol
intak
presenc
bulki
liver
surfac
detect
ultrasound
ct
presenc
sign
portal
hypertens
liver
biopsi
clinic
biochem
data
summar
tabl
tabl
studi
met
requir
approv
institut
review
board
respect
studi
site
accord
us
alf
studi
group
protocol
central
denmark
region
committe
health
research
ethic
approv
studi
regard
healthi
control
alcohol
cirrhosi
patient
presenc
sir
determin
occurr
least
two
follow
temperatur
higher
lower
white
cell
count
higher
l
lower
l
heart
rate
pco
mmhg
infect
defin
presenc
posit
urin
blood
cultur
chest
radiolog
sign
consist
pneumonia
mbllevel
quantifi
timeresolv
immuno
fluorometr
assay
trifma
sandwichtyp
immunoassay
short
microtitt
well
coat
mannan
block
human
serum
albumin
dilut
standard
control
sampl
ad
doubl
test
afterward
plate
incub
freshli
dilut
europiumlabel
monoclon
antimbl
final
enhanc
solut
ad
plate
read
timeresolv
fluorometri
mficolin
hficolin
level
quantifi
manner
similar
mbl
microtitt
well
coat
specif
antibodi
detect
carri
relev
biotinyl
specif
antibodi
thereaft
europiumlabel
streptavidin
plate
read
describ
respect
public
lficolin
level
analys
use
commerci
avail
enzymelink
immunosorb
assay
lficolin
elisa
kit
hycult
biotechnolog
interassay
imprecis
coeffici
variat
ie
cv
measur
mbl
mbl
level
respect
ie
differ
obtain
measur
five
differ
plate
mficolin
mficolin
level
lficolin
lficolin
level
hficolin
hficolin
level
level
three
qualiti
control
sampl
use
test
reflect
valu
dynam
rang
assay
present
microtitt
plate
use
concentr
lectin
pathway
protein
known
stabl
time
describ
previou
public
nonparametr
test
use
comparison
group
mannwhitney
test
unpair
data
wilcoxon
sign
rank
test
pair
data
correl
analys
spearman
rho
result
express
median
interquartil
rang
unless
otherwis
specifi
twotail
pvalu
consid
statist
signific
statist
analys
perform
use
stata
version
day
median
level
mbl
nearli
lower
alf
patient
healthi
control
vs
lower
alcohol
cirrhosi
patient
alf
patient
mbl
level
increas
day
day
fig
median
mficolin
level
lower
alf
patient
compar
healthi
control
vs
p
lower
alcohol
cirrhosi
patient
fig
median
lficolin
level
differ
alf
patient
healthi
control
vs
median
lficolin
level
alf
patient
higher
alcohol
cirrhosi
patient
fig
similarli
differ
hficolin
level
alf
patient
healthi
control
vs
howev
hficolin
level
alf
patient
nearli
twice
level
patient
alcohol
cirrhosi
p
fig
systemat
chang
l
hficolin
level
day
day
group
patient
accord
aetiolog
acetaminophen
drug
hepat
viral
hepat
indetermin
other
show
differ
mbl
ficolin
level
data
shown
differ
alcohol
cirrhosi
patient
healthi
control
regard
mbl
mficolin
level
alcohol
cirrhosi
patient
low
level
lficolin
vs
fig
fig
supplementari
materi
case
ficolin
day
patient
sir
higher
level
mficolin
patient
without
sir
vs
fig
supplementari
materi
differ
mbl
lor
hficolin
level
mbl
ficolin
correl
model
endstag
liver
diseas
meldscor
data
shown
survivalw
observ
signific
differ
mbl
lficolin
level
spontan
survivor
patient
die
patient
underw
liver
transplant
mbl
level
higher
day
spontan
survivor
compar
patient
transplant
die
vs
differ
disappear
day
vs
fig
day
median
lficolin
level
spontan
survivor
slightli
lower
compar
patient
transplant
die
vs
fig
biochem
correlationssignific
correl
found
mficolin
white
blood
cell
count
creatinin
inr
hficolin
creatinin
bilirubin
correl
observ
mbl
lficolin
biochem
marker
baselin
level
alf
patient
tend
higher
healthi
control
vs
level
increas
day
day
lead
significantli
higher
level
alf
patient
compar
healthi
control
median
level
day
lower
alf
patient
alcohol
cirrhosi
patient
vs
alcohol
cirrhosi
patient
higher
level
compar
healthi
control
vs
fig
group
patient
accord
aetiolog
show
level
acetaminophen
group
significantli
lower
compar
nonacetaminophen
induc
alf
day
compar
healthi
control
day
p
fig
level
associ
infect
sir
meldscor
correl
bilirubin
p
alt
p
level
correl
durat
symptom
durat
icteru
p
previou
studi
cohort
investig
macrophag
activ
marker
solubl
baselin
observ
signific
correl
p
addit
observ
weaker
signific
correl
mficolin
hficolin
correl
mbl
lficolin
central
find
studi
decreas
level
mbl
mficolin
increas
level
patient
alf
compar
healthi
control
well
associ
spontan
surviv
high
level
mbl
low
level
lficolin
result
demonstr
dynam
lectin
pathway
cours
alf
suggest
role
lectin
pathway
alf
though
causal
determin
base
studi
design
main
strength
studi
larg
cohort
longitudin
design
serum
sampl
day
day
major
patient
followup
case
report
week
time
death
transplant
allow
us
assess
dynam
chang
protein
level
earli
phase
alf
anoth
strength
comparison
patient
healthi
control
well
patient
stabl
alcohol
liver
cirrhosi
give
broader
pictur
lectin
pathway
acut
chronic
liver
diseas
studi
limit
fact
descript
studi
includ
collect
dna
genotyp
function
analys
conduct
determin
effect
observ
chang
observ
chang
lectin
pathway
protein
may
caus
differ
mechan
like
mechan
protein
releas
cell
due
differ
stimuli
mbl
like
releas
upon
product
wherea
unlik
mbl
ficolin
cytosol
protein
store
secretori
granul
hepatocyt
may
therefor
shed
bloodstream
hepatocyt
undergo
necrosi
apoptosi
alf
may
explain
level
higher
alf
patient
healthi
control
contrari
mbl
ficolin
previou
studi
shown
decreas
level
complement
protein
due
deposit
liver
may
explain
low
level
mbl
mficolin
therefor
function
mbl
may
remain
intact
patient
higher
level
mbl
caus
associ
high
level
mbl
relat
surviv
alf
possibl
explan
differenti
regul
synthesi
defect
protein
diseas
cours
genet
polymorph
respect
gene
differ
among
protein
due
differ
function
import
studi
clearli
demonstr
dynam
chang
lectin
pathway
protein
level
alf
patient
disput
gener
acut
hepat
synthesi
defect
indic
liver
preserv
capabl
secret
lectin
pathway
protein
despit
sever
liver
dysfunct
mbl
acut
phase
respons
may
possibl
studi
pneumococc
pneumonia
describ
mbl
genotyp
howev
describ
mbl
acut
phase
reactant
highli
controversi
mbl
respons
shown
high
degre
heterogen
associ
mbl
sirscriteria
level
mbl
mficolin
present
studi
line
find
studi
wherea
lficolin
level
gener
lower
higher
lower
hficolin
level
demonstr
previous
differ
may
partli
caus
use
differ
assay
antibodi
differ
chang
level
among
collectin
ficolin
observ
diseas
two
studi
describ
differ
chang
level
mbl
land
hficolin
preeclampt
women
patient
sarcoidosi
collectin
ficolin
level
correl
liver
statu
determin
meldscor
probabl
owe
larg
intraand
interindividu
variabl
patient
experienc
spontan
surviv
higher
level
mbl
lower
level
lficolin
indic
chang
lectin
pathway
protein
may
fact
part
diseas
process
product
chang
liver
statu
diseas
cours
though
observ
associ
surviv
result
clearli
help
determin
surviv
overlap
group
futur
studi
investig
mbl
genotyp
explain
effect
mbl
polymorph
prognost
factor
surviv
donor
recipi
genotyp
level
mbl
seem
prognost
factor
infect
surviv
liver
transplant
first
publish
studi
acut
chronic
liver
diseas
compar
healthi
control
newli
describ
protein
specul
activ
lectin
pathway
manner
similar
mbl
level
invers
correl
alt
normal
consid
reflect
hepatocyt
damag
level
posit
correl
bilirubin
secret
lead
idea
elev
level
reflect
prolong
damag
liver
also
consist
fact
correl
durat
symptom
icteru
interest
observ
low
level
acetaminophen
induc
alf
previou
studi
alf
patient
cohort
observ
significantli
increas
level
macrophag
activ
marker
observ
associ
may
explain
hepatocyt
necrosi
outflow
circul
parallel
activ
macrophag
like
caus
go
liver
cell
necrosi
inflamm
associ
hficolin
might
explain
similarli
main
focu
present
studi
comparison
alf
patient
healthi
control
howev
use
alcohol
cirrhosi
patient
addit
control
group
take
account
chronic
liver
diseas
differ
model
liver
failur
observ
mark
differ
two
group
mainli
lower
mbl
mficolin
level
higher
land
hficolin
level
compar
alf
patient
alcohol
cirrhosi
patient
previou
studi
mainli
studi
chronic
viral
hepat
found
differ
lficolin
level
hepat
c
patient
normal
alt
valu
healthi
control
low
level
mbl
patient
chronic
hepat
b
c
deviat
studi
may
caus
differ
alcohol
viral
caus
chronic
liver
diseas
conclus
observ
differenti
dynam
chang
lectin
pathway
protein
associ
mbl
lficolin
level
surviv
base
studi
determin
chang
function
clinic
signific
howev
studi
show
lectin
pathway
affect
alf
pave
road
studi
lectin
pathway
alf
refer
web
version
pubm
central
supplementari
materi
mical
campbel
univers
pennsylvania
philadelphia
pa
tarek
hassenein
fatma
barakat
univers
california
san
diego
ca
alistair
smith
duke
univers
durham
nc
studi
support
grant
danish
council
independ
research
medic
scienc
novo
nordisk
foundat
nation
institut
health
acut
liver
failur
level
day
day
patient
acut
liver
failur
accord
aetiolog
acetamin
acetaminophen
drug
hep
drug
hepat
viral
hep
viral
hepat
indeterm
indetermin
compar
healthi
control
p
compar
nonacetaminophen
case
x
compar
healthi
control
